|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 473/34 | |
| A61K 31/52 | |||
| A61P 35/00 | |||
| A61P 35/02 |
| (11) | Number of the document | 2834241 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13757230.1 |
| Date of filing the European patent application | 2013-03-05 | |
| (97) | Date of publication of the European application | 2015-02-11 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-18 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2013/029157 |
| Date | 2013-03-05 |
| (87) | Number | WO 2013/134288 |
| Date | 2013-09-12 |
| (30) | Number | Date | Country code |
| 201261606870 P | 2012-03-05 | US |
| (72) |
CARRA, Ernest, US
GERBER, Michael, US
SHI, Bing, US
SUJINO, Keiko, US
TRAN, Duong, US
WANG, Fang, US
EVARTS, Jerry, B., US
|
| (73) |
Gilead Calistoga LLC,
333 Lakeside Drive, Foster City. CA 94404,
US
|
| (54) | POLYMORPHIC FORMS OF (S)-2-(1-(9H-PURIN-6-YLAMINO)PROPYL)-5-FLUORO-3-PHENYLQUINAZOLIN-4(3H)-ONE |
| POLYMORPHIC FORMS OF (S)-2-(1-(9H-PURIN-6-YLAMINO)PROPYL)-5-FLUORO-3-PHENYLQUINAZOLIN-4(3H)-ONE |